Search PubMed⌕ Search

Biomedical subjects

G Brittinger

Publications and source records attributed to G Brittinger.

At least 91 records · Page 5Linked to original sources
PubMed1984

[Diagnosis of primary non-Hodgkin lymphomas of the central nervous system].

In literature, primary malignant lymphomas (PML) of the central nervous system (CNS) have been known for many years under different names, although diagnosis was almost exclusively made via autopsy. It is only since the existence of computed tomography (CT) that there is a possibility of identifying or at least presuming intra vitam such malignancy and of securing the diagnosis via brain biopsy. This is most important because it enables an early treatment of patients by means of radiation and chemotherapy. We are documenting a new approach to identify the PML of CNS by four case histories of our own patients. This consists in the specific manner in which these tumours react to high doses of corticosteroid therapy. Under this treatment they diminish in size or even disappear completely. This can even be seen in other diseases, but when such behaviour of an intracerebral lesion is seen in a CT scan it should be of help in the evaluation of differential diagnosis and should be regarded as an important pointer towards achieving early diagnosis of PML of the CNS.

Adult↗
PubMed1983

[Therapy of malignant lymphomas].

Prognostic factors in patients with Hodgkin's disease and the non-Hodgkin lymphomas are reviewed and discussed since they form the basis of the therapeutic approach to these conditions. Hodgkin's disease is treated according to stage, histology and other prognostic criteria and the appropriate management is presented in tabular form. In the non-Hodgkin lymphomas, prospective studies using the Kiel classification indicated that these lymphomas could be subdivided into types of low-, intermediate- and high-grade malignancy, each requiring different treatment modalities. An expectative approach is often, but not always, recommended in lymphomas of low malignancy. The natural history of lymphomas of high-grade malignancy is unfavourable and, usually, prolonged survival is observed only in those cases in which a complete remission is achieved. Our therapeutic approach to the various forms of these lymphomas is based on the stage of the disease and the respective schedules are summarized for lymphomas of low- and high-grade malignancy. Finally, the chances of cure in Hodgkin's disease and in the non-Hodgkin lymphomas are discussed and recent developments are mentioned.

Adolescent↗
PubMed1981

Histopathological correlation of the Kiel with the original Rappaport classification of malignant non-hodgkin lymphomas.

Using the Kiel and the Rappaport classifications, a comparative histopathological analysis of 486 cases with non-Hodgkin lymphomas from a prospective study of the Kiel Lymphoma Study Group, still in progress, was performed. The greater part of Rappaport's classical lymphoma entities was found to be inhomogeneous and to include tumors of considerable prognostic heterogeneity, as shown by differences in actuarial survival. Some of the Kiel lymphoma entities have been identified in several lymphoma types of the Rappaport classification, indicating that "translation" of one scheme into the other is difficult or impossible. In addition, centrocytic lymphoma of the Kiel classification may not be homogeneous. On the whole, the Kiel classification appears to be superior to the original Rappaport classification in categorizing the various prognostically diverse types of non-Hodgkin lymphomas.

Germany, West↗
PubMed1981

Lymphoplasmacytic/lymphoplasmacytoid lymphoma: a clinical entity distinct from chronic lymphocytic leukaemia?

Clinical data of 116 patients with chronic lymphocytic leukaemia (CLL) and of 114 patients with lymphoplasmacytic/lymphoplasmacytoid lymphoma (synonym: LP immunocytoma, IC) as diagnosed according to the Kiel classification were compared. This interim evaluation of a prospective multicenter study of the Kiel Lymphoma Study Group characterizes IC the less favorable lymphoma entity as evidenced by a more rapid lymph node enlargement, by a higher incidence of constitutional symptoms and of marked anaemia, and by a higher percentage of patients requiring early treatment. In addition, in IC autoimmune haemolytic anaemia was detected in 11.2% of investigated patients as compared to none of the patients with CLL, and monoclonal gammopathy was disclosed in 34.2% of investigated patients as compared to only three patients with CLL who could be, however, unrecognized cases of IC. Actuarial survival data after a follow-up period of 40 months are in favor of an overall better prognosis of patients with CLL than of patients with IC.

Adult↗
PubMed1981

Germinal center cell lymphomas: prognostic significance of their histopathological differentiation.

Clinical data of 48 patients with centrocytic, 83 patients with centroblastic/centrocytic and 64 patients with centroblastic lymphoma who had entered a prospective multicenter study of the Kiel Lymphoma Study Group since October 1975 were compared. Advanced (stage IV) disease at time of diagnosis, predominantly due to bone marrow infiltration, was most frequent in centrocytic (69% of patients) and in centroblastic/centrocytic (51% of patients) lymphomas as compared to only 28% of patients with centroblastic lymphoma. High survival probability of patients with localized centrocytic and centroblastic/centrocytic lymphomas after radiotherapy, contrasting with a worse prognosis of corresponding patients with centroblastic lymphoma, is compatible with the classification of these lymphoma entities as neoplasias of low-grade malignancy. However, as shown by this prospective and previous retrospective trials overall survival probability of patients with advanced centrocytic lymphoma was inferior to that observed in corresponding patients with centroblastic/centrocytic lymphoma. These findings suggest the possibility that patients with advanced centrocytic lymphoma occupy an intermediate position between typical low-grade and typical high-grade malignant non-Hodgkin lymphomas.

Adult↗
PubMed1981

Clinical and prognostic heterogeneity of non-Hodgkin lymphomas of high-grade malignancy.

Comparison of clinical data of 64 patients with centroblastic lymphoma, 55 patients with immunoblastic lymphoma and 31 patients with lymphoblastic lymphoma not only confirmed the original assumption of high-grade malignancy as proposed by the concept of the Kiel classification but also demonstrated distinct clinical differences, particularly between lymphoblastic lymphoma and the two other entities. Rapid lymph node enlargement as well as steep fall of survival curves within the first year after diagnosis were common characteristics. Bimodal age distribution, predominance of males and early generalization of disease were typical features of lymphoblastic lymphoma; elderly patients and patients with the unclassified subtypes of lymphoblastic lymphoma exhibited the worst prognosis. Whereas patients with centroblastic and immunoblastic lymphomas showed similar distribution of age, sex and initial stage of disease, patients with immunoblastic lymphoma presented more frequently with a reduced performance status and showed a poorer response to radio- and chemotherapy resulting in a worse prognosis discernible after the first year of follow-up. Generalization during course of the disease was significantly more frequent in immunoblastic than in centroblastic lymphoma.

Adolescent↗
PubMed1980

Sequential expression of fucosyltransferase and N-acetylneuraminyltransferase activities in human leukemic cells arrested at different stages of maturation.

Fucosyl transferase (Fuc-T) and N-acetylneuraminyl-transferase (NeuAc-T) activities were determined in lysates of human neoplastic hematopoietic cells arrested at different stages of maturation. Leukemic non-T/non-B lymphoblasts and myeloblasts arrested at a very early stage of maturation displayed high Fuc-T and low NeuAc-T activities. T-lymphoblasts, further developed along the T-lymphocyte lineage, showed increased NeuAc-T activity. In contrast, lymphoid cells further developed along the B-lymphocyte lineage revealed low Fuc-T, and either low or high levels of NeuAc-T activity. These results suggest that during the process of cell maturation the expression of Fuc-T precedes that of NeuAc-T, and that in T-lymphocytes the expression of NeuAc-T is concomitant with the emergence of the T-cell receptor for sheep erythrocytes.

Fucosyltransferases↗